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Abstract 
 
Hepatocyte transplantation (HT) is emerging as a promising alternative to orthotopic liver 
transplantation (OLT) in patients with certain liver-based metabolic disease and acute liver failure. 
Hepatocytes are generally infused into the portal venous system, from which they migrate into the liver 
cell plates of the native organ. One of the major hurdles to the sustained success of this therapy is early 
cell loss, with up to 70% of hepatocytes lost immediately following infusion. This is largely thought to 
be due to the instant blood-mediated inflammatory reaction (IBMIR), resulting in activation of 
complement and coagulation pathways. Transplanted hepatocytes produce and release tissue factor 
(TF), which activates the coagulation pathway leading to the formation of thrombin and fibrin clots. 
Thrombin can further activate a number of complement proteins leading to activation of the membrane 
attack complex and subsequent hepatocyte cell death. Inflammatory cells including granulocytes, 
monocytes, Kupffer cells and natural killer (NK) cells have been shown to cluster around transplanted 
hepatocytes leading to their rapid clearance shortly after transplantation. Current research aims to 
improve cell engraftment and prevent early cell loss. This has proved successful in vitro using 
pharmacological interventions such as melagatran, low-molecular weight dextran sulphate and N-
acetylcysteine (NAC). Effective inhibition of the IBMIR would significantly improve hepatocyte 
engraftment, proliferation and function, providing successful treatment for patients with liver-based 
metabolic diseases.  
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Introduction 
Hepatocyte transplantation (HT) offers a promising alternative to liver transplantation for patients with 
certain liver-based metabolic diseases and acute liver failure. Human hepatocytes are isolated from  
whole donor livers or tissue obtained from split liver procedures using a collagenase perfusion technique 
and purified using centrifugation (Fig. 1.) 1–4. The number of cells transplanted aims at approximating 
5% of the normal liver mass and are usually administered under radiological guidance via the portal 
vein or spleen.                                                   
HT has potential advantages over orthotopic liver transplantation (OLT) in certain cases because the 
procedure is less invasive with significantly less complications than organ transplantation. The 
technique can also provide temporary lifesaving treatment until a patient can undergo whole organ 
transplantation or potentially future gene therapy 2,5. HT can improve the phenotype of a number of 
metabolic liver diseases. To date, HT in patients with Crigler Najjar syndrome has been shown to 
decrease serum bilirubin levels by 30-60% and maintain the expression of UDP glucuronosyltransferase 
activity for up to 9 months 5–10. Furthermore, partial hepatectomy followed by hepatocyte 
transplantation  increased concentrations of hepatocyte growth factor (HGF), leading to increased 
hepatocyte function 11. Patients with factor VII deficiency have shown  up to a 70% decrease in the 
requirement for recombinant factor VII treatment 12 and in familial hypercholesterolemia there was up 
to a 70% decrease in LDL production 13. Phenotypic improvement has also been seen in glycogen 
storage disease (GSD) 1a and 1b with normal glucose-6-phosphatase activity and increased triglyceride 
levels observed 14,15 . Hepatocyte transplantation has also been shown to improve a number of urea cycle 
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defects including; ornithine transcarbamylase (OTC) deficiency where patients showed a decrease in 
ammonia production and an increase in urea production 16,17 argininosuccinate lysase (ASL) deficiency 
in which there was sustained hepatocyte engraftment with increased ASL activity 18 and tyrosinemia 
type 1 which improved clotting factor levels and decreased bilirubin concentrations 19. Such promising 
results suggest HT has clinical potential in alleviating the severity of metabolic liver diseases, making 
day to day management easier and improving quality of life for patients. . Although hepatocyte 
transplantation has great potential, there are still many bottle necks that limit the efficacy of the 
technique. This includes the scarcity of donor organs, the decreased viability of cells due to 
cryopreservation, early cell loss and the lack of engraftment into the liver. So far, only rarely have 
patients with metabolic disease demonstrated a sustained  long-term improvement in their condition 
following HT 18. 
Pathophysiology of the IBMIR   
Though immunosuppression is generally used in hepatocyte transplantation for liver-based metabolic 
conditions, early cell loss due to the innate immune response has not been successfully targeted. 
Transplantation of hepatocytes, islets of Langerhans and therapies involving mesenchymal stem cells 
have all been associated with cell damage and significant cell loss very soon after administration, 
leading to poor engraftment and cell function 20.  
Early hepatocyte cell loss has been demonstrated in dipeptidyl peptidase IV-deficient F344 rats, which 
showed hepatocytes present in large numbers in portal areas shortly after transplantation 21. There was 
significant clearance of hepatocytes from these portal areas and low engraftment into the liver sinusoids 
with an average 3.3 fold decline of the total number of transplanted hepatocytes between 2 and 24 hours 
21. This significant cell clearance was attributed to the presence of granulocytes, phagocytes and 
activated macrophages surrounding the hepatocytes in portal areas within 6 hours post transplantation  
21. This has been confirmed clinically with explanted livers from metabolic liver disease patients who 
had undergone hepatocyte transplantation followed by OLT. Patients were shown to have inflammatory 
thrombi containing lymphocytes, histocytes and multinucleated macrophages post HT 22.  
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This inflammatory reaction is now commonly referred to as the  instant blood-mediated inflammatory 
reaction (IBMIR), in which cells are recognised by the innate immune system, leading to rapid 
activation of both complement and coagulation pathways 23. Additionally, inflammatory cells including 
granulocytes, monocytes, kupffer cells and natural killer (NK) cells are activated leading to rapid 
clearance and death of transplanted hepatocytes 24. IBMIR induced cell loss has been well described in 
islet transplantation in both in vitro blood perfusion systems, rodent and primate studies and in patients 
undergoing clinical islet transplantation 25–29. 
 
The coagulation cascade is usually activated following endothelial cell surface damage, leading to 
activation of fVIIa. Hepatocytes have been shown to trigger activation of the extrinsic coagulation 
cascade by producing tissue factor which binds to factor VII (fVII) and fVIIa, leading to the activation 
of fVIIa (Fig 2). The TF-VIIa complex initiates the activation and cleavage of factor X (fX), producing 
fXa which associates with co-factor Va to form the prothrombinase complex which converts 
prothrombin to thrombin 30. Thrombin initiates the conversion of fibrinogen to fibrin and activates factor 
XIII to promote fibrin cross linking and the formation of fibrin clots. Thrombin also amplifies its own 
expression through activation of cofactor VIII to VIIIa which binds factor IXa to further activate fX. 
Thrombin activates platelets by binding to receptors on their cell surface and is required for their 
aggregation and formation of clot structure.  
 
The complement and coagulation cascade share similar characteristics with both consisting of 
circulating zymogens, that rely upon a series of enzymatic reactions, producing an active protease and 
a non-enzymatic ligand 31,32. There are over 30 complement proteins, however the most important is 
complement component 3 (C3). The complement cascade consists of 3 distinct pathways including the 
alternative, classical, and lectin pathway, however all lead to the cleavage of C3 into C3a and C3b by 
C3 convertase (Fig.2). The alterative pathway is the first to act and is directly activated by binding of 
the C3b fragment to the foreign cell surface, targeting it for destruction by phagocytes, while the smaller 
C3a fragment acts as a chemoattractant for phagocytes and other inflammatory cells 32. The lectin 
pathway is activated by mannose binding lectin (MBL) which circulates in plasma in its inactive form 
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in complex with MBL-associated protease (MASP) 1 and 2. The MBL complex binds to mannose 
containing carbohydrates on the foreign surface 32. Lastly, the classical pathway is activated when C-
reactive protein or immunoglobulins such as IgM, IgG bind to specific antigens on a target surface.  All 
3 pathways lead to the covalent binding of C3b to the foreign surface. C3b binds to C3 convertase 
producing C5 convertase which results in the cleavage of C5 into C5a and C5b. C5b triggers the 
terminal pathway and initiates the formation of the membrane attack complex, which creates pores in 
the target cell membrane 33. The liver is a major source of complement proteins, primarily produced by 
inflammatory cells and hepatocytes. Interestingly it has been shown that hepatocytes synthesise up to 
15 times more C3 than macrophages 34.  
 
Interactions between the complement and coagulation pathways are poorly understood (Fig. 2.). 
Complement proteins may directly enhance coagulation through platelet activation and modification of 
the lipid membrane, resulting in activation of TF  31. Furthermore, thrombin may also have a role in 
amplifying the complement cascade 35. Krisinger et al. showed thrombin efficiently cleaved C5 at a 
newly identified site, R947 generating C5T and C5bT 35. The crosstalk between such related biological 
cascades has clinical importance with evidence suggesting an inhibitor of the coagulation cascade may 
also prevent activation of the complement pathway, reducing the effects of the IBMIR with a single 
inhibitor 23.  
 
Activation of both complement and coagulation pathways leads to the stimulation of a number of 
inflammatory cells including neutrophils, monocytes, macrophages and natural killer (NK) cells (Fig 
3). Macrophages or kupffer cells in the liver  are responsible for phagocytosis of foreign cells, and 
translocation of NF-κB to the macrophage nucleus initiates  translocation of a number of inflammatory 
cytokines including IL-1, IL-2, IL-6, IL-12 and CXCL-8 32. These act as chemokines for a number of 
inflammatory cells such as neutrophils and NK cells. Neutrophils function in a similar way to 
macrophages, producing a number of degradative enzymes and granules to lyse the target cell. NK cells 
are lymphocytes that circulate in an active state and act through IFN-γ production and through receptor 
mediated binding that allows distinction between foreign and innate cells.  
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Thus, activation of processes such as coagulation, complement and inflammatory cell recruitment have 
the potential to cause significant harm to transplanted cells, preventing engraftment and the success of 
the transplant. Current research has aimed to discover the possibility and mechanisms of IBMIR 
induced hepatocyte cell loss and investigate reliable and effective methods of preventing this occurring.  
 
 
Activation of coagulation in Hepatocyte Transplantation  
 
A single stage clotting assay showed hepatocytes in contact with human plasma resulted in pro-
coagulant activity (PCA) that increased significantly with increasing concentrations of hepatocytes. 
PCA was absent in factor VII-deficient plasma, further suggesting the role of TF in coagulation 
activation. A chandler loop model was designed in which polyvinyl chloride (PVC) tubing was coated 
with heparin, incubated at 37 degrees and placed on a rocker to generate a flow of 45ml/minute to mimic 
portal vein blood flow. Using this model, it was shown 5x105 hepatocytes induced clot formation in 
ABO-matched blood circulating for 30 minutes. This correlated with a significant drop in platelet count 
and increased D-dimer levels 36. The same authors have shown pro-coagulant activity in human adult 
liver-derived mesenchymal progenitor cells. Thromboelastography revealed shorter clotting times in 
plasma and whole blood treated with hepatocytes, while the tubing loop model revealed a significant 
drop in platelet count and increased D-dimer levels 37.  
 
The source of TF in HT was directly tested in mouse models of acetaminophen (APAP) overdose 38. 
Following HT, thrombin anti-thrombin (TAT) expression in plasma was significantly higher in wild 
type mice transplanted with control hepatocytes compared to wild type mice receiving hepatocytes from 
genetically modified mice with selectively deleted TF expression 38. This proves donor hepatocytes are 
the source of pro-coagulant TF, triggering the IBMIR.  
Activation of coagulation  following HT has been demonstrated clinically in a child with ornithine 
transcarbamylase deficiency 23. An hour following intraportal infusion of 8.3x107 cryopreserved 
hepatocytes there was a significant increase in TAT, FXI-anti-thrombin, FXII-anti-thrombin and 
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platelet depletion 23. This suggests activation of the IBMIR within 60 minutes of HT. Similarly, a 9 
month-old girl with Crigler-Najjar syndrome received 2.6 billion cryopreserved hepatocytes over 2 
weeks in 14 infusions. The patient showed increased D-dimer levels but normal fibrinogen, prothrombin 
time and activated partial thromboplastin time 36. The authors suggest cell dependent coagulation may 
occur in the small liver sinusoids and therefore may not be detected in high peripheral and portal flow  
36
.  Evidence of thrombosis has also been demonstrated in explant livers of children with metabolic 
livers that received hepatocyte transplantation. Hepatocytes, identified by the bile salt export protein 
(BSEP) were found in the portal vein thrombi 22.  
 
Activation of complement in Hepatocyte Transplantation  
 
Complement activation of C3a and C5b-9 has been demonstrated in a tubing loop model containing 
ABO matched human blood and 1x105 fresh hepatocytes 23. The addition of melagatran, a direct 
thrombin inhibitor and low molecular-weight dextran sulfate (LMW-DS), an anti-thrombotic agent, 
reduced both TAT expression and C3a expression, further suggesting the association between the 
complement and coagulation cascade. Melagatran, a thrombin inhibitor reduces the generation of 
thrombin through the production of chondroitin sulphate and indirectly inhibits the complement 
system.39,40.   
Complement activation has been implicated in the acute death of allogenic rat models following 
intraportal infusion of rat hepatocytes 41. Transplantation of WAG-Rij hepatocytes into Lewis rat 
participants resulted in high morbidity rates and large thrombi containing complement components 
including C3 and IgM. No deaths occurred when WAG-Rij hepatocytes were transplanted into WAG-
Rij rats 41.  Lewis rat recipients pre-treated with the complement inhibitor, cobra venom factor had high 
survival, suggesting complement activation was a vital contributor to the higher morbidity rates 41.  
The role of complement activation in HT has further been investigated using transfected hepatocytes. 
Hammel et al. infected hepatocytes with an adenovirus containing the genes encoding the hCMV 
promoter and the human CR1 receptor, which is a potent inhibitor of the C3 and C5 convertases, 
essential in the classical and alternative complement pathways 42,43. Transplantation of hepatocytes 
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expressing the CR1 adenovirus prevented immediate rejection in immunocompetent Nagase 
analbuminemic rats and increased albumin production. Such genetic modification of hepatocytes may 
be useful in reducing complement activation following transplantation into sensitized recipients 43.  
 
 
Infiltration of inflammatory cells  
 
Once administered via the portal vein, transplanted hepatocytes become entrapped into the liver 
sinusoids, migrate across the endothelial barrier and integrate into the parenchyma 23,44. However, the 
presence of transplanted hepatocytes within the sinusoids temporarily occludes blood flow and activates 
ischaemia-reperfusion events  45. Ischaemia-reperfusion leads to the activation of Kupffer cells which 
are specialised macrophages residing in liver sinusoids, responsible for the clearance of transplanted 
hepatocytes and the 70% cell loss observed following transplantation 45.  Gadolinium chloride (GdCl3) 
has been used to deplete Kupffer cells and increase hepatocyte cell survival 45. Control rats showed 
transplanted cells in 34% of liver radicles compared to 66% in GdCl3 treated rats 72 hours following 
transplantation. Furthermore, approximately 2-fold more hepatocytes were observed in the periportal 
sinusoids and the liver parenchyma 1, 2 and 7 days following transplantation. The authors suggest 
inhibition of Kuffper cell activation offers a way to prevent early cell loss following transplantation and 
improve engraftment of transplanted hepatocytes.  
 
Inflammatory cells from the recipient liver have also been demonstrated to stimulate activation of a 
number of cytokine-chemokine genes within 3 weeks post hepatocyte transplantation 46.This included 
chemokine ligands, chemokine receptors, and regulatory cytokines. In the DPPIV rat model, gene 
expression levels of cytokine-chemokine genes increased from 2- to over 120-fold. Depletion of 
Kupffer cells and neutrophils resulted in the normalisation of 19 of 25 genes. This was associated with 
increased cell engraftment for up to 2 weeks 46.  
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NK cells have also been shown to accumulate around transplanted hepatocytes 24. Wesolowska et al. 
developed a combined protocol of non-lethal whole body irradiation, administration of anti-asialoGM1 
anti-serum (to eliminate NK cells) and reconstitution with bone marrow cells, to eliminate inflammatory 
cell activation following transplantation. Lewis rats received this combined treatment over 3 days before 
transplantation of syngenic hepatocytes into the spleen. Such treatment led to the formation of 
hepatocyte islands 14 days following transplantation which increased in number at 30 days. 
Immunohistochemical staining revealed the absence of cytotoxic granulocytes, macrophages and NK 
cells 47. Combined treatment may be a potential way to eliminate inflammatory cells involved in the 
innate immune response and prevent early hepatocyte cell loss. However, clinically the risks of such 
treatment may need to be considered.   
 
 It is also important to consider the potential benefit of the inflammatory response. To a certain extent, 
kupffer cell production of cytokines such as interleukin, TNF-α and free radicals  are important  for 
endothelial disruption which is necessary for transplanted hepatocytes to cross the endothelial barrier 
and enter the sinusoidal plates 21,48. It may be important to consider the effects complete inhibition of 
the inflammatory response has upon the hepatocyte translocation and engraftment. It may be more 
effective to dampen the response but not cause complete inhibition.   
 
Current therapeutic strategies to inhibit the IBMIR 
Inhibition of the IBMIR has been well explored in the setting of islet transplantation using a variety of 
different methods (Table 1).  This includes systemic anti-coagulant drugs such melagatran, low-
molecular weight dextran sulphate and NAC. These have been shown to inhibit platelet consumption, 
decrease the expression of complement and coagulation proteins and reduce the number of 
inflammatory cell subtypes in blood perfusion models 49,50. Several anti-inflammatory proteins have 
also been investigated in vivo. This includes alpha-1 antitrypsin (AAT) and activated protein C, which 
have been shown to down-regulate the expression of a number of inflammatory cytokines and improve 
islet survival and engraftment in mouse models of islet transplantation 51–54. An anti-TF antibody 
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decreased post-transplant markers of coagulation following islet transplantation in cynomolgus 
monkeys, resulting in higher C-peptide levels and prolonged graft function 29. A novel approach has 
been to coat cell surfaces with macromolecular heparin complexes 28. Tubing loops with heparin coated 
islets resulted in no macroscopic clotting and the generation of TAT and drop in platelet count were 
significantly attenuated compared to untreated loops 28.  Alternatively, it is possible to coat the cell 
surface of islets with poly-ethylene glycol (PEG), which allows binding of a number of different anti-
inflammatory proteins such as sCR155,56.  
Mesenchymal stem cells have also been shown to trigger the IBMIR after exposure to human blood, 
with activation dependent on the cell passage number. The authors showed visible clot formation in the 
Chandler loop model which was prevented by addition of the anti-TF blocking agent FVIIai and by 
monoclonal anti-TF antibodies 57.  
Currently only a limited number of anti-inflammatory drugs have been tested to inhibit the IBMIR in 
the context of hepatocyte transplantation.  
 
Therapeutic strategies to inhibit the IBMIR in hepatocyte transplantation 
 
Systemic Administration  
Gustafson et al. studied a number of systematic coagulation inhibitors to minimise the IBMIR in HT 
and investigated the effect of thrombin inhibition, a factor VIIa inhibitor (iFVIIa) and an anti-TF 
monoclonal antibody. In a tubing loop model, both inhibitors prevented platelet consumption after 15 
minutes but this was not maintained after 30 minutes. iFVIIa did not significantly decrease the 
concentration of coagulation factors TAT, FXIIa-AT, FXIa-AT, and complement factors C3a and C5b-
9G 23. In contrast,  the direct thrombin inhibitor Melagatran (10µM) and low molecular weight dextran 
sulphate prevented platelet depletion and significantly decreased concentrations of TAT, FXIIa-AT, 
FXIa-AT, C3a and C5b-9G after 60 minutes 23.  
 
The anti-oxidant NAC, has been shown to inhibit the activity of thrombin and coagulation factorsVII 
and X 58. NAC has been shown to inhibit PCA in whole blood containing hepatocytes in a dose 
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dependent manner 36. Pro-coagulant activity was significantly lower in plasma containing hepatocytes 
and 10- 25mM/L NAC. Furthermore, platelet counts and D-dimer concentrations were maintained at a 
similar level to the control 36.  
 
In human adult liver-derived mesenchymal progenitor cells (hALPCs), the combination of bivalirudin 
and heparin treatment inhibited reduced clotting time and improved both engraftment and cell survival 
37.  
 
Encapsulation  
An alternative approach to prevent activation of the IBMIR response following HT, is to encapsulate 
cells in microbeads made from purified alginate 59. The semi-permeable membrane within the 
microbeads allows glucose and oxygen to pass through, maintaining necessary metabolic function, 
whilst also protecting against immunocompetent cells by preventing the entry of antibodies 55,60. 
Encapsulating hepatocytes in alginate microbeads improved the survival of mice with acute liver failure 
by providing metabolic support, decreasing the number of cytokines and reducing the inflammatory 
stress on the liver 59. However, the encapsulation of cells using alginate or agarose can produce large 
capsules that make transplantation into the liver through the portal vein difficult, as major blood vessels 
would be occluded 55.  Teramura et al. carried out microencapsulation of cells in an ultra-thin polymer 
membrane, which showed reduced platelet aggregation, decreased TAT levels and lower levels of C3a 
and C5b compared to alginate coated cells when exposed to human whole blood and serum 55.  
 
Cytotopic Therapeutic Agents  
Currently, novel cytotopic therapeutic agents are being investigated as a novel way to target the IBMIR 
in both whole organ transplantation and cell transplantation. Such agents are designed to bind to the 
cell membrane of transplanted cells and provide local inhibition of complement and coagulation 
pathways without the need for systemic treatment which may result in bleeding risk. Currently cytotopic 
agents such as Mirococept are being developed and investigated for kidney, islet and hepatocyte 
transplantation as well as the prevention of myocardial and intestinal ischaemia reperfusion injury 61–64. 
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Mirococept is derived from the human complement regulatory protein CR1, a transmembrane protein 
found on the cell surface of inflammatory cells 42. CR1 is a potent inhibitor of the C3 and C5 convertases 
42. In both rat kidney transplantation and human tumour nephrectomy specimens, immunohistochemical 
analysis showed Mirococept localized to the glomerular and tubular structures of the kidney. After 24 
hours, neutrophil activity and deposition of C3a and C5-9 was significantly lower in Mirococept treated 
grafts compared to controls  65. In 2012, 76 patients had received Mirococept including one liver patient. 
These initial results showed Mirococept had no adverse side effects and the next step is a multicentre 
phase 2b clinical trial 42. 
 
Conclusions  
Evidence of the instant blood-mediated inflammatory reaction has been demonstrated following HT in 
both blood perfusion models, animal experiments and patients. Transplanted hepatocytes produce and 
release TF, leading to activation of coagulation and complement pathways and eventually cell lysis. 
Inflammatory cells are further activated leading to the rapid clearance of hepatocytes shortly after 
transplantation. Such activation of the innate immune response following HT is a limiting factor to the 
success of this technique. Current research in HT aims to reduce this early cell loss and improve cell 
engraftment. This includes pharmacological interventions, cell encapsulation and novel cytotopic 
therapeutic agents. Improved cell engraftment and survival will significantly increase the application of 
HT and provide treatment for patients who are unsuitable or unable to receive orthotopic liver 
transplantation.  
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IBMIR inhibitor Mechanism Results Reference 
    
 
Low-molecular 
weight dextran 
sulphate 
 
Anti-thrombin inhibitor 
 
Inhibited macroscopic clotting, 
reduced platelet consumption 
and inhibited the production of 
C3a, FXIa-AT and TAT 
 
49 
N-acetyl cysteine  Inhibitor of coagulation 
factors II, VII and X 
Inhibited TF expression and 
decreased pro-coagulant activity  
 
66 
Melagatran  Anti-thrombin inhibitor  
 
Decreased TAT, FXIa-AT and 
C3a expression 
 
39  
Alpha-1 antitrypsin  Serine protease inhibitor 
that can cleave pro 
inflammatory and 
coagulation proteins.  
 
Down-regulated inflammatory 
cytokines and increased islet 
survival in mouse models.  
51 
Activated protein C 
 
 
Anti-inflammatory, anti-
thrombotic properties 
Improvements in factor VII 
levels, reduction in clot weight, 
improved platelet, neutrophil 
and monocyte counts and 
improved fibrinogen and D-
dimer levels. 
 
52 
Monoclonal anti-TF Anti-tissue factor  Decreased coagulation factors, 
higher CP levels and increased 
graft survival.   
 
29 
Heparin Inhibitor of anti-thrombin Heparin coated islets resulted in 
no macroscopic clotting and the 
generation of TAT and drop in 
platelet count were significantly 
attenuated. 
 
28 
Surface 
Modification With 
Poly(ethylene 
glycol)-Lipid and 
Urokinase 
 
Coating of islets to 
prevent direct exposure to 
blood  
Insulin levels increased after 
transplantation in recipient mice.  
67 
Table 1: Inhibitors of the IBMIR and their mechanisms of action in islet transplantation  
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Figure Legends 
 
Figure 1. Isolation of human hepatocytes. Hepatocytes are isolated from donor liver tissue using a 
collagenase perfusion technique and purified using centrifugation. Cells are either transplanted 
directly into the portal vein or cryopreserved for emergency cases. Viability and metabolic activity is 
checked before administration via the portal vein 
 
Figure 2. Activation of the instant blood-mediated inflammatory reaction following hepatocyte 
transplantation. Transplanted hepatocytes produce and release TF which binds to the coagulation 
factor VIIa and initiates the activation and cleavage of factor Xa, which is responsible for the conversion 
of prothrombin to thrombin. This is followed by platelet binding to the cell surface and the conversion 
of fibrinogen to fibrin forming fibrin clots. Thrombin has also been shown to activate complement 
proteins. C3 activates C3 convertase resulting in the cleavage of C3 to C3a and C3b, which activates 
C5 convertase, resulting in the cleavage of C5 to C5a and C5b-9. C5b is responsible for the production 
of the membrane attack complex (MAC) which binds to the membrane of target cells resulting in cell 
lysis.  
Figure 3. Intravenously transplanted hepatocytes cause activation of inflammatory cells 
including; neutrophils, monocytes, Kupffer cells and NK cells. Such inflammatory cells recognise 
transplanted hepatocytes and activate mechanisms including; receptor mediated phagocytosis, cytokine 
and chemokine production, and the production of cytotoxic granules such as fas and perforin. Activation 
of such inflammatory responses contribute to hepatocyte cell lysis and death.  
  
Copyright © 2016 Cognizant Communication Corporation 
 
21 
CT-1556 Cell Transplantation early e-pub; provisional acceptance 03/09/2016 
 
Figure 1 
  
Copyright © 2016 Cognizant Communication Corporation 
 
22 
CT-1556 Cell Transplantation early e-pub; provisional acceptance 03/09/2016 
 
Figure 2 
  
Copyright © 2016 Cognizant Communication Corporation 
 
23 
CT-1556 Cell Transplantation early e-pub; provisional acceptance 03/09/2016 
 
Figure 3 
